Lindsay Peterson, MD, MSCR

Medical Oncologist

Lindsay Peterson

Appointment Options

Whether you’re seeking a new patient appointment or exploring treatment options and looking for a second opinion, our Siteman care coordinators are ready to assist you.

My Locations

Expertise & Training

Video thumbnail for Lindsay Peterson, MD, MSCR

Watch video on YouTube

Lindsay Peterson, MD, MSCR

3 mins

Washington University medical oncologist Lindsay Peterson, MD, MSCR, discusses what breast cancer patients can expect from their extended care team at Siteman Cancer Center. Learn more about Dr. Peterson: https://siteman.wustl.edu/doctor/peterson-lindsay/

Learn more about the Siteman Approach to Breast Cancer: https://siteman.wustl.edu/treatment/cancer-types/breast-cancer/our-approach/

Learn more about all breast cancer treatment options at Siteman Cancer Center: https://siteman.wustl.edu/treatment/cancer-types/breast-cancer/treatments/

Hear from Siteman patients who discuss their journey with breast cancer diagnosis, treatment and recovery: https://siteman.wustl.edu/treatment/cancer-types/breast-cancer/patient-stories/

Clinical Expertise

Primary Academic Title

Associate Professor, Division of Medical Oncology, WashU Medicine

Board Certification

  • 2009: American Board of Internal Medicine
  • 2013: American Board of Internal Medicine, Medical Oncology
  • 2014: American Board of Internal Medicine, Hematology

Training

  • 2006 - 2007: Intern, Internal Medicine, University of Texas Health Science Center, San Antonio, TX
  • 2007 - 2009: Resident, Internal Medicine, University of Texas Health Science Center, San Antonio, TX
  • 2010 - 2013: Fellow, Hematology and Medical Oncology, University of Texas Health Science Center, San Antonio, TX

Education

  • 2006: MD, Tulane University, New Orleans, LA
  • 2016: MSCR< Medical University of South Carolina, Charleston, SC

Research & Selected Publications

Research Interest

Improving breast cancer outcomes through lifestyle interventions including diet and exercise.

Research Publications

Biomarkers of response to neoadjuvant palbociclib plus anastrozole in endocrine-resistant estrogen receptor-positive/HER2-negative breast cancer: a phase 2 trial
Authors:

Kong T, Mabry A, Highkin M, one or more additional authors omitted Peterson L, one or more additional authors omitted Ma CX

Journal & Year:

Nat Commun | 2026

Detection of Circulating Tumor DNA Using a Tissue-Free Epigenomic Assay Is a Highly Prognostic Biomarker in Early-Stage Triple-Negative Breast Cancer
Authors:

Ademuyiwa FO, Ma CX, Weilbaecher K, one or more additional authors omitted Peterson LL, one or more additional authors omitted Davis A

Journal & Year:

Clin Cancer Res | 2025

NCCN Guidelines® Insights: Survivorship, Version 2.2025
Authors:

Sanft T, Day AT, Ansbaugh SM, one or more additional authors omitted Peterson LL, one or more additional authors omitted Freedman-Cass D

Journal & Year:

J Natl Compr Canc Netw | 2025

NCCN Guidelines® Insights: Survivorship, Version 2.2024
Authors:

Sanft T, Day AT, Goldman M, one or more additional authors omitted Peterson L, one or more additional authors omitted Freedman-Cass D

Journal & Year:

J Natl Compr Canc Netw | 2024

Dietary and serum advanced glycation end-products and clinical outcomes in breast cancer
Authors:

Peterson LL, Ligibel JA

Journal & Year:

Biochim Biophys Acta Rev Cancer | 2024

NCCN Guidelines® Insights: Survivorship, Version 1.2023
Authors:

Sanft T, Day A, Ansbaugh S, one or more additional authors omitted Peterson L, one or more additional authors omitted Freedman-Cass DA

Journal & Year:

J Natl Compr Canc Netw | 2023